首页|不同HER2水平乳腺癌临床病理特征及预后

不同HER2水平乳腺癌临床病理特征及预后

扫码查看
目的 分析HER2低表达乳腺癌临床病理特征、预后和影响因素.方法 收集2016年1月-2023年6月绵阳市中心医院收治的HER2阴性乳腺癌患者资料,分为HER2(0)、HER2(1+)和HER2(2+)3组.比较临床病理特征及生存情况差异,多因素Cox回归分析HER2低表达乳腺癌预后影响因素.结果 3组间N分期和HR差异具有统计学意义(P<0.01).在HR+亚组中,3组间N分期差异具有统计学意义(P<0.01),HR-亚组纳入指标差异无统计学意义(P>0.05).3组间总生存时间和无病生存时间曲线无显著差异.多因素Cox回归分析,T2~4、N1~3和Ki-67>14%的HER2低表达乳腺癌具有更高的无病生存时间缩短的风险(P<0.05),T2~4和N1~3的HER2低表达乳腺癌具有更高的总生存时间缩短的风险(P<0.05).结论 HER2低表达乳腺癌N分期高和HR+比例高,预后无显著差异.
Clinicopathological features and prognosis of breast cancer with different level human epidermal growth factor receptor
Objective To analyze the clinicopathological characteristics and prognosis of patients with low HER2 expression and explore the prognostic factors.Methods The clinicopathological and prognostic data was collected from the HER2 negative breast cancer patients who were admitted to Mianyang Central Hospital.The patients were divided in-to 3 groups,Including HER2(0),HER2(1+)and HER2(2+).The differences in clinicopathological features,overall survival(OS)and disease-free survival(DFS)of the three groups were compared,and the prognostic factors of HER2 low expression breast cancer were analyzed by the univariate and multivariate Cox proportional hazard regression.Results In the overall cases,there were statistical significances in the difference of N stage(P<0.01)and HR(P<0.01)between the three groups.In the HR+subgroup,there was statistical significance in the difference of N stage(P<0.01)between the three groups.In the HR-subgroup,there was no statistical significance in the included indicators.There was no sig-nificant difference in the OS and DFS between the three groups.The multi-variate analysis results by Cox proportional hazards regression found that the HER2 low expression breast cancer patients with T2~4,N1~3 and Ki-67>14%had higher risks of DFS shortening(P<0.05),and the low HER2 expression breast cancer patients with T2~4 and N1~3 had the higher risks of OS shortening(P<0.05).Conclusion The HER2 low expression breast cancer patients have the higher N stage and more HR+,however,there is no significant difference in the OS and DFS be-tween HER2(0)and HER2 low expression breast cancer.

Breast cancerHuman epidermal growth factor receptor 2 low expressionHER2 negativeClinico-pathologic featuresPrognosis

岳芳静、徐卫云、刘思雨

展开 >

西南医科大学附属医院乳腺外科,四川泸州 646000

绵阳市中心医院乳腺外科,四川绵阳 621000

乳腺癌 HER2低表达 HER2阴性 临床病理特征 预后

2025

西部医学
四川

西部医学

影响因子:1.352
ISSN:1672-3511
年,卷(期):2025.37(1)